Study on the infusion-site adverse events and vascular distribution of epirubicin in chemotherapy with epirubicin and fosaprepitant

In breast cancer patients on a fluorouracil-epirubicin (EPI)-cyclophosphamide (FEC) regimen and intravenous fosaprepitant (FAP) during chemotherapy, infusion-site adverse events such as vascular pain and induration and/or phlebitis are observed. In the present study, adverse events induced by the FE...

Descripción completa

Detalles Bibliográficos
Autores principales: Yamasaki, Miho, Kimura, Ryuji, Mayahara, Shigeri, Maeda, Yorinobu, Takahashi, Mamoru, Nishida, Toshihiro, Oda, Keisuke, Murakami, Teruo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: D.A. Spandidos 2019
Materias:
Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6535639/
https://www.ncbi.nlm.nih.gov/pubmed/31289676
http://dx.doi.org/10.3892/mco.2019.1849

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6535639/
https://www.ncbi.nlm.nih.gov/pubmed/31289676
http://dx.doi.org/10.3892/mco.2019.1849

Ejemplares similares